DHSC payment received

RNS Number : 7091R
Abingdon Health PLC
07 July 2022
 

Abingdon Health plc

("Abingdon" or "the Company")

 

DHSC payment received

 

York, U.K. 7 July 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, provides an update on the resolution of the outstanding payment with Department for Health & Social Care ("DHSC") .

 

On 28 June 2022 the Company announced that it had reached a settlement with the DHSC on the outstanding invoices due from DHSC to Abingdon.

 

Abingdon can confirm that it has today received the £6.3m cash payment from DHSC as part of the settlement agreement.

 


Enquiries:

 

Abingdon Health plc

www.abingdonhealth.com/investors/

Chris Yates,  Chief Executive Officer

Via Walbrook PR

Melanie Ross , Chief Financial Officer

 

Dr Chris Hand,  Non-Executive Chairman

 

 

 

Singer Capital Markets (Sole Broker and Nominated Adviser)

Tel: +44 (0)20 7496 3000

Shaun Dobson, Peter Steel, Alex Bond (Corporate Finance)

 

Tom Salvesen (Corporate Broking)

 

 


Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or  abingdon@walbrookpr.com

Paul McManus / Phillip Marriage

Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082

Alice Woodings

Mob: +44 (0)7407 804 654


About Abingdon Health plc

 

Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

 

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCRRMBTMTIMBLT
UK 100

Latest directors dealings